Hormone replacement therapy in the prevention and treatment of atherosclerosis.
As the population ages, the increasing number of women at risk for cardiovascular disease represents both a potential crisis and an opportunity in healthcare management. Although the overall death rate from cardiovascular disease in the general population is decreasing, the absolute numbers for women are increasing. A reduction in modifiable risk factors in women must be aggressively pursued by clinicians and health systems. Menopause is associated with many adverse effects on cardiovascular-disease risk factors in women. Estrogen replacement therapy has been shown to favorably influence many risk factors for cardiovascular disease. Despite this biologic plausibility and supporting evidence from epidemiologic studies, data from confirmatory clinical trials are lacking. Because of this, recommendations for hormone replacement therapy should be made on an individual basis.
Mosca
L
L
Preventive Cardiology, New York Presbyterian Hospital, Irving Center for Clinical Research, PH 10-305, 622 West 168th Street, New York, NY 10032, USA.
D000818:Animals; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D016021:Epidemiologic Studies; D004967:Estrogens / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D020249:Hormone Replacement Therapy; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D050356:Lipid Metabolism; D017698:Postmenopause / Q000502:physiology*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
D004967:Estrogens